endogena's CEO presents latest research at World Alliance Forum
Our CEO Matthias Steger presented the latest results of endogena's three currently ongoing projects among world leading experts in the field of regenerative medicine at the World Alliance Forum in San Francisco, entitled "Healthcare Game Changers: Innovations in Science, Policy & Business for Healthy Aging".
CCRM joins endogena's group of investors
endogena therapeutics is pleased to announce that the Centre for Commercialization of Regenerative Medicine (CCRM) joins the group of investors to support the company's endeavour to discover and develop first-in-class endogenous regenerative medicines. Michael May, President and Chief Executive Officer of CCRM: "We are excited about the prospects for endogena therapeutics and look forward to help to achieve the company's long-term objectives for success."
endogena co-founder honored with Herman Skolnik Award
Prof. Gisbert Schneider has received the Herman Skolnik Award from the American Chemical Society for his life-time achievements in the area of de novo design of bioactive molecules.
endogena at New York venture summit
endogena will be presenting at this year's New York venture summit on July 11th. Please contact us at email@example.com to schedule 1:1 meetings.
endogena presents at JLABS Toronto
At the highly attended two year anniversary of JLABS Toronto on May 10th, our VP discovery biology, Daphna Mokady, explained endogena's platform approach for endogenous regeneration.
enabling transformational impact
recent breakthroughs in stem cell biology together with technological advances for phenotypic, functional screening have unlocked our ability to harness the potential of adult stem- and precursor cells. our novel drug discovery approach is based on the concept of selective activation of endogenous progenitor cells for controlled tissue repair and regeneration by small molecules.
endogena therapeutics is a pioneer in the discovery and development of first-in-class endogenous regenerative medicines.
nobel laureate Shinya Yamanaka’s breakthrough discovery that mature cells can be transformed into stem cells has opened the way to the therapeutic potential of regulating endogenous stem cells by small molecule medicines. harnessing this knowledge opens the door to new potential in addressing unmet medical needs associated with degenerative diseases, including genetic diseases and those resulting from ageing.
our transformational drug discovery paradigm is based on the concept of selective activation of endogenous progenitor cells for controlled tissue repair and regeneration.
endogena uses artificial intelligence to elucidate the links between structures of small molecules and their effect on lineage-specific differentiation pathways - our platform enables the identification of molecular modulators of progenitor cell regeneration, specific to tissues and organs.
we apply small-molecule medicines to target degenerative diseases caused by aging or genetic disorders without the complexity (regulatory, production, distribution, application etc.) of genetic engineering or cellular transplantation therapies.
in our lead program, we have identified ways in which neuroectoderm pathway retinal progenitor cells can be targeted by small-molecule medicines to restore vision.
stem cell science meets small-molecule medicine
stem cells are the regenerative units of our body - they replenish our tissues constantly, and help fight disease and ageing - they accomplish their task by producing progenitor cells that give rise to specialized cells through a process called differentiation - different types of endogenous stem cells reside in the respective tissues they constantly regenerate – retinal stem cells in the eye, for example.
degenerative diseases are common and becoming more prevalent due to demographic changes - but these diseases could, in principle, be rescued by stem cells. the opportunity offered by endogena therapeutics’ approach bears the potential for a dramatic improvement on existing therapies.
in our lead program, we are targeting degenerative diseases of the eye, including retinitis pigmentosa, which progressively leads to complete loss of vision – our pioneering approach enables the discovery of breakthrough therapies based on cutting-edge knowledge of molecular pathways that regulate retinal stem cells and retinal pigment epithelial cells, which nourish the eye’s photoreceptors and retina.
endogena is building and integrating
a novel, proprietary platform that allows the redefinition of drug discovery, starting directly from developmental biology - the accurately defined network of pathways orchestrated by nature to ensure the unobstructed assembly of all multicellular organisms has divulged its operating modes over the recent decades.
endogena utilizes its proprietary smeragd™
(stem-cell modifying effect relationship analyzer guided design) platform to assist in the design and conceptualization of compounds - smeragd™ combines theories derived from developmental biology for specific progenitor cell stimulation with real-world chemistry-driven phenotypic stem cell alterations and pharmacophore features.
a given compound’s involvement
in a known mode of action is simultaneously tracked and successfully predicted. this allows for an accurate stem cell lineage specific separation between compound effects on proliferation and differentiation - collectively, the output from these evaluations is used to tailor a chemical design strategy customized to a specific target.
at endogena, we strongly believe in the innovation potential by collaboration – accordingly, we work with world-leading partners in academia and industry to leverage state-of-the-art discoveries and technologies
stem cell biology
leading academic institutions
- biological testing
- retinal regeneration assays
artificial intelligence & machine learning
- molecular design
- virtual screening
- compound logistics
- VP medicinal chemistry
- endogena therapeutics, inc.
111 pine street | san francisco
ca 94111 | usa
- binzmuehlestrasse 170a
ch-8050 zuerich | switzerland